Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | GNRHR | P30968 | 7/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861144 | 0.90 | GBA1 (0.51) | GBA1BCAT2PRMT3 | |
| SCHEMBL1206387 | 0.90 | GBA1 (0.51) | GBA1BCAT2PRMT3 | |
| SCHEMBL14861146 | 0.90 | GBA1 (0.51) | GBA1BCAT2PRMT3 | |
| Hydrochloric Acid SCHEMBL9716119 | 0.88 | GBA1 (0.50) | GBA1BCAT2PRMT3 | |
| Trifluoroacetic Acid SCHEMBL15663554 | 0.86 | DPP7 (0.41) | DPP8DPP7 | |
| SCHEMBL28165335 | 0.85 | GBA1 (0.45) | GBA1BCAT2TACR1PRMT3 | |
| SCHEMBL1230763 | 0.81 | CNR2 (0.44) | TACR1 | |
| SCHEMBL382192 | 0.79 | PNMT (0.50) | TACR1 | |
| SCHEMBL15664192 | 0.79 | GBA1 (0.40) | GBA1BCAT2TACR1PRMT3 | |
| SCHEMBL15663752 | 0.78 | HDAC3 (0.42) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126998-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | Bayer Pharma AG (DE) | 2015-09-08 | — | — | US | disclosed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | GBA1 1708/4885BCAT2 42/4885GNRHR 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.